Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Johnson & Johnson Celebrates COVID-19 Vaccine Science Superheroes

Katalin Karikó, Ph.D. and Drew Weissman, M.D. Ph.D. Receive 2021 Dr. Paul Janssen Award for Uncovering Ways to Safely Use mRNAs in Vaccines and Therapeutics

(PRNewsfoto/Johnson & Johnson)

News provided by

Johnson & Johnson

Sep 28, 2021, 07:00 ET

Share this article

Share toX

Share this article

Share toX

NEW BRUNSWICK, N.J., Sept. 28, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced Katalin Karikó, Ph.D. of BioNTech Pharmaceuticals and the University of Pennsylvania and Drew Weissman, M.D., Ph.D., of the University of Pennsylvania as winners of the 2021 Dr. Paul Janssen Award for Biomedical Research. The duo were honored for their foundational work that enabled the use of messenger RNA in the development of COVID-19 vaccines, and holds tremendous promise for development of future vaccines and therapeutics.

The company also recognized other scientists from across academia, government and industry who have worked tirelessly since the start of the pandemic to bring COVID-19 vaccines to the world as "Vaccine Science Superheroes" and donated $100,000 in their honor to IntraHealth International – a non-profit organization supporting front-line health workers tackling COVID-19.

"Among the dozens of nominations of deserving researchers, the work of Drs. Karikó and Weissman stood out not only for the impact it is already having on the COVID-19 pandemic, but also for the potential it holds for preventing and treating other serious diseases," said Richard P. Lifton, M.D., Ph.D., President of The Rockefeller University and Dr. Paul Janssen Award committee chair.

Karikó and Weissman were selected as the 2021 winners by an independent committee of world-renowned scientists. They join 19 scientists who have received the Dr. Paul Janssen Award since 2004, including five who went on to win the Nobel Prize.

"It is a great honor to recognize the work of researchers like Dr. Karikó and Dr. Weissman, and all of the COVID-19 vaccine science superheroes who embody the same curiosity, perseverance and commitment to improving human health as Dr. Paul Janssen," said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson. "They persevered in the face of so many obstacles along their science journey, and today their work is helping save millions of lives all over the world."

Johnson & Johnson will honor these remarkable scientists during a live webcast program "Eureka Moments: Vaccine Science Superheroes" on September 28, 2021 at 11:00 a.m. ET via Johnson & Johnson's page on LinkedIn. The program will showcase the scientists behind the headlines whose Eureka moments are improving human health, including perspectives from Drs. Karikó and Weissman and other scientists involved in developing COVID-19 vaccines including: Dr. Dan Barouch, Beth Israel Deaconess Medical Center; Professor Sarah Gilbert, Oxford; Dr. Tonya Villafana, AstraZeneca; Dr. Andrea Carfi, Moderna; Drs. Hanneke Schuitemaker1 and Shirley Sylvester2, Johnson & Johnson. The broadcast also will feature a fireside chat about what COVID-19 has taught the world about health equity.

"While I am accepting the Dr. Paul Janssen Award for Biomedical Research, I reflect on my humble beginning, the support of my family, teachers, mentors and colleagues who helped me on my journey," said Dr. Karikó. "I think about all those hard-working fellow scientists who are so passionate about their work and immensely contributed to the success of the COVID-19 mRNA vaccine."

"I am greatly honored to receive this award, but the honor really goes to all basic science researchers who made the modified mRNA-LNP vaccines for COVID-19 possible," said Dr. Weissman.

"Now more than ever, the world needs science to come to the rescue," said Seema Kumar, Global Head, Office of Innovation, Global Health and Scientific Engagement, Johnson & Johnson. "We are pleased to recognize the extraordinary scientists behind the COVID-19 vaccines, and to showcase the dedicated men and women who are behind the lab coat and on the frontlines of the fight against serious diseases. They are a special squad of superheroes. 'Eureka!' moments is our attempt to bring you their stories."

About the Dr. Paul Janssen Award for Biomedical Research

Dr. Paul Janssen was one of the 20th century's most gifted and passionate researchers. He helped save millions of lives through his contribution to the discovery and development of more than 80 medicines, four of which remain on the World Health Organization's list of essential medicines.

The Dr. Paul Janssen Award for Biomedical Research was established by Johnson & Johnson in 2004 to honor the memory of Dr. Paul. Since its inception, the Award has recognized 19 outstanding scientists, five of whom have gone on to win the Nobel Prize for the same work. Winners are chosen by an independent selection committee of the world's most renowned scientists. The Award includes a $200,000 prize.

Previous winners include:

  • 2020 – Lewis Cantley, Ph.D.
  • 2019 – Franz-Ulrich Hartl, M.D., and Arthur Horwich, M.D.
  • 2018 – James Allison, Ph.D.  Nobel Laureate
  • 2017 – Douglas Wallace, Ph.D.
  • 2016 – Yoshinori Ohsumi, Ph.D.  Nobel Laureate
  • 2015 – Bert Vogelstein, M.D.
  • 2014 – Emmanuelle Charpentier, Ph.D. and Jennifer Doudna, Ph.D.  Nobel Laureates
  • 2013 – David Julius, Ph.D.
  • 2012 – Victor Ambros, Ph.D., and Gary Ruvkun, Ph.D.
  • 2011 – Napoleon Ferrara, M.D.
  • 2010 – Anthony S. Fauci, M.D. and Erick De Clercq, M.D., Ph.D.
  • 2009 – Axel Ullrich, Ph.D.
  • 2008 – Sri Ravinder Maini, FRCP, FMedSci, FRS and Marc Feldmann, FMedSci, FAA, FRS
  • 2006 – Craig Mello, Ph.D., Nobel Laureate

Learn more about The Dr. Paul Janssen Award at www.pauljanssenaward.com

About Johnson & Johnson

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. To learn more, visit www.jnj.com 

1 Janssen Vaccines & Prevention B.V.

2 Office of the Chief Medical Officer, Johnson & Johnson

SOURCE Johnson & Johnson

Related Links

https://www.jnj.com/

21%

more press release views with 
Request a Demo

Modal title

Also from this source

Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting

Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting

Johnson & Johnson (NYSE: JNJ) today announced plans to initiate the first head-to-head study comparing FcRn blockers for patients with generalized...

New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile

New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile

Johnson & Johnson (NYSE: JNJ) today announced findings from the U.S. dataset from the global ENCOMPASS study evaluating patient and healthcare...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Biotechnology

Biotechnology

Infection Control

Infection Control

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.